Literature DB >> 29417838

Lung cancer: a brief review of epidemiology and screening.

Cláudia Gouvinhas1, Ramon Andrade De Mello2,3,4,5, Daniela Oliveira1, José Manuel Castro-Lopes1, Pedro Castelo-Branco2,3, Ricardo Sales Dos Santos6, Venceslau Hespanhol7,8, Daniel Humberto Pozza9.   

Abstract

The global burden of lung cancer has been increasing over the past years, and is still a major threat to public health worldwide, leading to disabilities and premature mortality. Despite multifactorial cause, smoking remains as the major etiological factor, followed by occupational exposure to carcinogens, genetic predisposition and other concomitant diseases. In order to reduce the individual and social burden due to the direct and indirect costs related to the lung cancer treatment, accurate methods of screening are needed. Among those, x-ray with cytological analysis of sputum was first proposed. Nowadays, more sensitive methods such as low-dose computed tomography are being used to improve the early detection. In the future, molecular biomarkers may complement low-dose computed tomography and improve the robustness of early lung cancer detection.

Entities:  

Keywords:  biomarkers; epidemiology; low-dose computed tomography; lung cancer screening; smoking

Mesh:

Substances:

Year:  2018        PMID: 29417838     DOI: 10.2217/fon-2017-0486

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  9 in total

1.  MetaLanc9 as a novel biomarker for non-small cell lung cancer: promising treatments via a PGK1-activated AKT/mTOR pathway.

Authors:  Ramon Andrade De Mello; Pedro Nazareth Aguiar; Hakaru Tadokoro; Tállita Meciany Farias-Vieira; Pedro Castelo-Branco; Gilberto de Lima Lopes; Daniel Humberto Pozza
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

2.  Treatment Sequencing Strategies in Lung Cancer.

Authors:  Daniel Humberto Pozza; Ramon Bezerra Andrade de Mello
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2022-05-20

3.  Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study.

Authors:  Zhi-Yong He; Mei-Fang Li; Jing-Hui Lin; Dong Lin; Ren-Jang Lin
Journal:  Cancer Manag Res       Date:  2019-03-14       Impact factor: 3.989

4.  Genetic polymorphisms in IL-7 and IL-7R are correlated with lung cancer risk in the Chinese Han population.

Authors:  Chan Zhang; Pincan Su; Wanlu Chen; Qi Li; Run Dai; YuJing Cheng; Jiangcun Yang
Journal:  Cancer Manag Res       Date:  2019-06-11       Impact factor: 3.989

5.  Transthoracic fine-needle aspiration diagnosis of solid, subsolid, and partially calcified lung nodules: A retrospective study from a single academic center.

Authors:  Yangying Zhou; Gary Gong; Haiyan Wang; Zahra Alikhassy Habibabady; Peggy Lang; Russell Hales; Frederic Askin; Ed Gabrielson; Qing Kay Li
Journal:  Cytojournal       Date:  2019-08-22       Impact factor: 2.091

6.  Current and future aspects of TIM-3 as biomarker or as potential targeted in non-small cell lung cancer scope: is there a role in clinical practice?

Authors:  Ramon Andrade De Mello; Jin-Hui Zhu; Jairo Iavelberg; Artur Henrique Potim; Débora Simonetti; José Antônio Silva; Pedro Castelo-Branco; Daniel Humberto Pozza; Carla Chizuru Tajima; Maria Tolia; Georgio Antoniou
Journal:  Transl Lung Cancer Res       Date:  2020-12

7.  miR‑654‑3p suppresses cell viability and promotes apoptosis by targeting RASAL2 in non‑small‑cell lung cancer.

Authors:  Jie Xiong; Shigang Xing; Zheng Dong; Lei Niu; Qinghua Xu; Yusheng Li; Pingyi Liu; Peixia Yang
Journal:  Mol Med Rep       Date:  2020-12-10       Impact factor: 2.952

Review 8.  Role of circulating tumor cell spheroids in drug resistance.

Authors:  Gerhard Hamilton; Barbara Rath
Journal:  Cancer Drug Resist       Date:  2019-09-19

9.  Subtyping Lung Cancer Using DNA Methylation in Liquid Biopsies.

Authors:  Sandra P Nunes; Francisca Diniz; Catarina Moreira-Barbosa; Vera Constâncio; Ana Victor Silva; Júlio Oliveira; Marta Soares; Sofia Paulino; Ana Luísa Cunha; Jéssica Rodrigues; Luís Antunes; Rui Henrique; Carmen Jerónimo
Journal:  J Clin Med       Date:  2019-09-19       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.